[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Verge J, Albiol J, Navas M, Martín C: [Primary angiosarcoma of the spleen with liver metastases. Case report and literature review]. Cir Esp; 2005 Jul;78(1):50-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary angiosarcoma of the spleen with liver metastases. Case report and literature review].
  • [Transliterated title] Angiosarcoma primario de bazo con metástasis hepáticas: presentación de un caso y revisión de la bibliografía.
  • Angiosarcomas of the spleen are infrequent tumors that often present with liver metastases.
  • Immunohistochemical markers can aid preoperative diagnosis since radiological and ultrasonographic images are fairly nonspecific.
  • The recommended treatment is splenectomy.
  • The benefits of chemotherapy and radiotherapy have not been clearly demonstrated.
  • [MeSH-major] Hemangiosarcoma / secondary. Hemangiosarcoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Splenic Neoplasms / pathology. Splenic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Splenectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420791.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med; 2007 Jul-Aug;21(4):764-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
  • BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs.
  • At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs.
  • Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols.
  • Therefore, we evaluated the safety and effectiveness of LDC using a combination of cyclophosphamide, etoposide, and piroxicam as adjuvant therapy for dogs with stage II HSA.
  • HYPOTHESIS: We hypothesized that oral adjuvant therapy with LDC could be safely administered to dogs with HSA and that survival times would be comparable to those attained with conventional doxorubicin (DOX) chemotherapy.
  • ANIMALS: Nine dogs with stage II splenic HSA were enrolled in the LDC study.
  • Treatment outcomes were also evaluated retrospectively for 24 dogs with stage II splenic HSA treated with DOX chemotherapy.
  • METHODS: Nine dogs with stage II splenic HSA were treated with LDC over a 6-month period.
  • Adverse effects and treatment outcomes were determined.
  • Overall survival times and disease-free intervals were compared between the 9 LDC-treated dogs and 24 DOX-treated dogs.
  • RESULTS: Dogs treated with LDC did not develop severe adverse effects, and long-term treatment over 6 months was well-tolerated.
  • Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days.
  • By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.
  • CONCLUSIONS: Continuous orally administered LDC may be an effective alternative to conventional high-dose chemotherapy for adjuvant therapy of dogs with HSA.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708397.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86224-01; United States / NCRR NIH HHS / RR / RR00707
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down


3. Shiba M, Takatera H, Tokizane T, Terakawa T: [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report]. Hinyokika Kiyo; 2003 Aug;49(8):463-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report].
  • A 32-year-old man who had previously undergone chemotherapy for testicular seminoma 11 years ago was admitted to our hospital with a pain in the right leg.
  • Computed tomography (CT) and bone scintigraphy revealed splenomegaly and multiple bone disease.
  • The pathologic diagnosis of the resected spleen and the biopsied rib was angiosarcoma.
  • We found no reports of angiosarcoma following previous chemotherapy for testicular cancer.
  • It is unclear whether the angiosarcoma is a secondary neoplasm induced by the chemotherapy or not.
  • The chemotherapy might also have affected the chromosomal aberration presumably in endothelial progenitor cells causing the development of a secondary neoplasm.
  • To our knowledge, this is the first case of angiosarcoma after chemotherapy for testicular seminoma.
  • [MeSH-major] Hemangiosarcoma / etiology. Neoplasms, Second Primary / etiology. Seminoma / drug therapy. Splenic Neoplasms / etiology. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518382.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Hara T, Tsurumi H, Kasahara S, Ogawa K, Takada J, Imai K, Takai K, Kitagawa J, Kiyama S, Imai N, Oyama M, Takami T, Moriwaki H: Long-term survival of a patient with splenic angiosarcoma after resection, high-dose chemotherapy, and autologous peripheral blood stem cell transplantation. Intern Med; 2010;49(20):2253-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with splenic angiosarcoma after resection, high-dose chemotherapy, and autologous peripheral blood stem cell transplantation.
  • FDG-PET revealed a hot spot in the whole spleen.
  • Histological examination was typical for angiosarcoma.
  • Adjuvant chemotherapy was given, and high-dose chemotherapy with autologous peripheral blood stem cell transplantation was performed.
  • Thrombocytopenia developed again in 2008.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / therapy. Peripheral Blood Stem Cell Transplantation. Splenectomy. Splenic Neoplasms / therapy
  • [MeSH-minor] Catheter Ablation. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Hepatectomy. Humans. Interleukin-3 / therapeutic use. Middle Aged. Prednisone / administration & dosage. Recombinant Proteins / therapeutic use. Thrombocytopenia / etiology. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962445.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-3; 0 / Recombinant Proteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Kim SE, Liptak JM, Gall TT, Monteith GJ, Woods JP: Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). J Am Vet Med Assoc; 2007 Nov 15;231(10):1550-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
  • OBJECTIVE: To determine the efficacy and toxic effects of epirubicin for the adjuvant treatment of dogs with splenic hemangiosarcoma and identify prognostic factors.
  • ANIMALS: 59 client-owned dogs that underwent splenectomy for splenic hemangiosarcoma treated with or without epirubicin.
  • For dogs treated with epirubicin, dose numbers, intervals, and reductions and type and severity of toxic effects were recorded.
  • Dogs were allotted to 2 groups: splenectomy alone and splenectomy with adjuvant epirubicin treatment.
  • RESULTS: 18 dogs received epirubicin (30 mg/m(2)) every 3 weeks for up to 4 to 6 treatments.
  • The overall median survival time was significantly longer in dogs treated with splenectomy and epirubicin (144 days), compared with splenectomy alone (86 days).
  • Median survival time for dogs with stage I disease (345 days) was significantly longer than for dogs with either stage II (93 days) or III disease (68 days).
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dog Diseases / drug therapy. Epirubicin / therapeutic use. Hemangiosarcoma / veterinary. Splenic Neoplasms / veterinary
  • [MeSH-minor] Animals. Chemotherapy, Adjuvant / veterinary. Dogs. Female. Male. Prognosis. Retrospective Studies. Splenectomy / veterinary. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021000.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


6. Mutsaers AJ: Metronomic chemotherapy. Top Companion Anim Med; 2009 Aug;24(3):137-43
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metronomic chemotherapy.
  • Chemotherapy drugs are usually administered at doses that are high enough to result in an obligatory break period to allow for the observation of potential side effects and institution of supportive care, if required.
  • In recent years, efforts to administer chemotherapy on a more continuous basis, with a much shorter break period, or none at all, have received increased interest, and the practice has come to be known as metronomic chemotherapy.
  • The basis for success with this currently investigational approach may be rooted in continuous drug exposure to susceptible cancer cells, inhibition of tumor blood vessel growth-a process known as tumor angiogenesis, and/or alterations in tumor immunology.
  • Increased benefit also appears to occur when metronomic chemotherapy is used in combination with newer, targeted antiangiogenic agents, and therefore represents a promising approach to combination therapy, particularly as targeted oncology drugs make their way into veterinary oncology applications.
  • There is still much to be learned in this field, especially with regard to optimization of the proper drugs, dose, schedule, and tumor applications.
  • However, the low cost, ease of administration, and acceptable toxicity profiles potentially associated with this therapeutic strategy make metronomic chemotherapy protocols attractive and suitable to veterinary applications.
  • Preliminary clinical trial results have now been reported in both human and veterinary medicine, including adjuvant treatment of canine splenic hemangiosarcoma and incompletely resected soft tissue sarcoma, and, further, more powerful studies are currently ongoing.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases / drug therapy. Sarcoma / veterinary. Soft Tissue Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Drug Administration Schedule

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732732.001).
  • [ISSN] 1938-9736
  • [Journal-full-title] Topics in companion animal medicine
  • [ISO-abbreviation] Top Companion Anim Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 56
  •  go-up   go-down


7. Rupolo M, Berretta M, Buonadonna A, Stefanovski P, Bearz A, Bertola G, Canzonieri V, Morassut S, Frustaci S: Metastatic angiosarcoma of the spleen. A case report and treatment approach. Tumori; 2001 Nov-Dec;87(6):439-43
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angiosarcoma of the spleen. A case report and treatment approach.
  • We report a case of a 28-year-old man with angiosarcoma of the spleen and liver metastases.
  • The aim of this paper is to underline the importance of planned splenectomy in these patients even if they have metastatic disease, and to propose an intensive chemotherapy regimen consisting of anthracyclines, ifosfamide and mesna with G-CSF support.
  • [MeSH-major] Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Palliative Care. Quality of Life. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989602.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Culp WT, Drobatz KJ, Glassman MM, Baez JL, Aronson LR: Feline visceral hemangiosarcoma. J Vet Intern Med; 2008 Jan-Feb;22(1):148-52
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feline visceral hemangiosarcoma.
  • BACKGROUND: Feline visceral hemangiosarcoma (HSA) is an uncommon tumor, and the clinical progression and outcome are rarely reported.
  • Tumor location was identified in the following organs: liver (35%), small intestine (31%), large intestine (31%), abdominal lymph node (31%), mesentery (27%), spleen (23%), lung (19%), omentum (12%), brain (8%), pancreas (8%), and diaphragm (8%).
  • Three cats received adjuvant chemotherapy (doxorubicin).
  • Seventy-one percent of euthanized cats were euthanized within 1 day of diagnosis.
  • The median survival time of the remaining cats (n = 6) was 77 days (range, 23-296 days).
  • CONCLUSION AND CLINICAL IMPORTANCE: Feline visceral HSA is most often multifocal at the time of diagnosis.
  • The prognosis appears poor, and the number of cats receiving chemotherapy is low.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289302.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Maier A, Bataille F, Krenz D, Anthuber M: [Angiosarcoma as a rare differential diagnosis in spontaneous rupture of the spleen]. Chirurg; 2004 Jan;75(1):70-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma as a rare differential diagnosis in spontaneous rupture of the spleen].
  • A splenectomy was performed in a 37-year-old woman because of spontaneous rupture of the spleen.
  • Primary angiosarcoma of the spleen was diagnosed postoperatively based on histology.
  • Primary angiosarcoma of the spleen is a very rare neoplasm with disastrous prognosis.
  • Immunohistochemical and ultrastructural examinations are necessary to verify the diagnosis because the histopathological picture of the tumor is variable.
  • Due to the small number of reported cases, there are no guidelines for adjuvant or palliative therapy, and up to today all adjuvant means of radiotherapy and chemotherapy have not improved the prognosis of the patients.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Radiography, Abdominal. Rupture, Spontaneous. Spleen / pathology. Time Factors. Tomography, Spiral Computed. Tomography, X-Ray Computed. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Rontgenpraxis. 1999;52(3-4):137-9 [10522455.001]
  • [Cites] Pathologe. 2001 Sep;22(5):343-8 [11572116.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):300-4 [6894525.001]
  • [Cites] Eur J Surg. 1991 Mar;157(3):215-7 [1678633.001]
  • [Cites] Acta Biomed Ateneo Parmense. 2000;71(5):135-40 [11450114.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(4):226-30 [9445970.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):398-403 [11355176.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):109-14 [12116058.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Arch Pathol Lab Med. 1979 Mar;103(3):122-4 [581838.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Mar;14(3):289-92 [10197502.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2400-6 [8635113.001]
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):152 [9591036.001]
  • [Cites] Dtsch Med Wochenschr. 1992 Dec 22;117(51-52):1971-5 [1478172.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):989-96 [7842420.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Arch Pathol Lab Med. 1992 Oct;116(10):1079-82 [1384457.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Aug;27(4):231-5 [11721736.001]
  • [Cites] Hautarzt. 2000 Jul;51(7):479-85 [10969401.001]
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):439-43 [11989602.001]
  • (PMID = 14740131.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Hsu JT, Chen HM, Lin CY, Yeh CN, Hwang TL, Jan YY, Chen MF: Primary angiosarcoma of the spleen. J Surg Oncol; 2005 Dec 15;92(4):312-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the spleen.
  • BACKGROUND AND OBJECTIVES: Primary splenic angiosarcoma is a very rare and aggressive neoplasm with a high metastatic rate and dismal prognosis.
  • METHODS: The records of all cases of primary splenic angiosarcoma treated at Chang Gung Memorial Hospital from April 1991 to July 2004 were retrospectively reviewed.
  • Hemoperitoneum due to splenic rupture was noted in one patient.
  • Three patients had distant metastasis to the liver (n = 2), bone (n = 1), bone marrow (n = 1), and small bowel (n = 1) at diagnosis.
  • Liver (n = 3), bone (n = 1), and bone marrow (n = 1) metastases were found in four patients after initial therapy.
  • Five of the six cases underwent a splenectomy, one underwent partial hepatectomy, and one received chemotherapy.
  • The respective 1-, 3- and 5-year survival rates were 60%, 40%, and 40%, and the median survival time was 36 months.
  • CONCLUSIONS: The clinical presentations of splenic angiosarcoma were similar to those of previous reports apart from the higher rate of splenomegaly observed in this study.
  • [MeSH-major] Hemangiosarcoma. Splenic Neoplasms
  • [MeSH-minor] Adult. Aged. Child. Disease-Free Survival. Female. Gastrointestinal Hemorrhage / etiology. Hemoperitoneum / etiology. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Splenectomy. Splenic Rupture / etiology. Splenomegaly / etiology. Thrombocytopenia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299797.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. den Hoed ID, Granzen B, Granzen B, Aronson DC, Pauwels P, de Kraker J, van Heurn LW: Metastasized angiosarcoma of the spleen in a 2-year-old girl. Pediatr Hematol Oncol; 2005 Jul-Aug;22(5):387-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasized angiosarcoma of the spleen in a 2-year-old girl.
  • Primary angiosarcoma of the spleen is rare and the prognosis is very poor.
  • The authors present a 2-year-old girl with spontaneous rupture of splenic angiosarcoma.
  • At diagnosis there were liver metastases.
  • After splenectomy she received chemotherapy with ifosfamide, vincristine, and actinomycine D combined with a partial liver resection.
  • She remained in complete remission over 2 years from diagnosis.
  • [MeSH-major] Hemangiosarcoma / secondary. Liver Neoplasms / secondary. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Female. Hepatectomy. Humans. Neoplasm Metastasis. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020128.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Wang C, Rabah R, Blackstein M, Riddell RH: Bone marrow metastasis of angiosarcoma. Pathol Res Pract; 2004;200(7-8):551-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow metastasis of angiosarcoma.
  • We report a rare finding of bone marrow metastasis from an angiosarcoma.
  • The patient was a 36-year-old man who initially presented with a high-grade angiosarcoma of the spleen and was treated with splenectomy and chemotherapy.
  • He developed leukoerythroblastic anemia three years after splenectomy.
  • Bone marrow biopsy revealed extensive infiltrate by angiosarcoma with typical features of spindle tumor cells and anastomosing vascular channels.
  • We have found in the literature two other cases of bone marrow metastasis of angiosarcoma, and all these patients had a primary tumor of the spleen.
  • It would seem that splenic angiosarcomas have a virtually unique propensity for infiltration in the bone marrow.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Hemangiosarcoma / secondary. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462503.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / von Willebrand Factor
  • [Number-of-references] 10
  •  go-up   go-down


13. Sorenmo K, Samluk M, Clifford C, Baez J, Barrett JS, Poppenga R, Overley B, Skorupski K, Oberthaler K, Van Winkle T, Seiler G, Shofer F: Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med; 2007 Nov-Dec;21(6):1347-54
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
  • BACKGROUND: Canine splenic hemangiosarcoma (HSA) is a fatal malignancy, and most affected dogs die within a few months of diagnosis.
  • ANIMALS: Fourteen dogs with splenic HSA.
  • Results of the postmortem examination and pharmacokinetic analysis confirmed that IP delivery of doxorubicin resulted in an effective drug concentration with a clearance comparable with that after i.v. delivery.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196746.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


14. Muzi MG, Rulli F, Federico F: Angiosarcoma of the spleen mimicking rupture. Case report and literature review. Acta Biomed Ateneo Parmense; 2000;71(5):135-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen mimicking rupture. Case report and literature review.
  • Primary angiosarcoma of the spleen is very rare and only 143 cases have previously been reported.
  • The prognosis is very poor in any case and survival isn't more than two years: wherever the spleen undergoes spontaneous rupture the survival should be less than six months.
  • Patients with or without metastatic disease may be treated by chemotherapy but with poor results.
  • We report the clinical case concerning a 79-years-old man with liver metastases and a 5-cm lesion in the spleen, where a subcapsular rupture was suspected.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450114.001).
  • [Journal-full-title] Acta bio-medica de L'Ateneo parmense : organo della Società di medicina e scienze naturali di Parma
  • [ISO-abbreviation] Acta Biomed Ateneo Parmense
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 25
  •  go-up   go-down


15. Hamid KS, Rodriguez JA, Lairmore TC: Primary splenic angiosarcoma. JSLS; 2010 Jul-Sep;14(3):431-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic angiosarcoma.
  • Primary splenic angiosarcoma is a rare, aggressive malignant neoplasm arising from splenic vascular endothelium.
  • Splenic enlargement with heterogeneous enhancement was identified on CT of the abdomen.
  • Laparoscopic splenectomy was performed, and a primary splenic angiosarcoma was discovered.
  • After 2 rounds of chemotherapy, a CT scan showed progressive disease with metastasis to the liver and lung.
  • Primary splenic angiosarcoma is almost universally fatal despite treatment.
  • The best chance for survival is early diagnosis and prompt splenectomy prior to splenic rupture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Med Pediatr Oncol. 2003 Jun;40(6):411-2 [12692821.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):1137-63 [15256634.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):319-24 [7196486.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):702-8 [8310831.001]
  • [Cites] South Med J. 1995 Aug;88(8):873-5 [7631220.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2400-6 [8635113.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):827-35 [9236839.001]
  • [Cites] Radiology. 2005 Apr;235(1):106-15 [15749977.001]
  • [Cites] Pediatr Surg Int. 2007 Aug;23(8):807-10 [17641924.001]
  • [Cites] J Natl Med Assoc. 2000 Mar;92(3):143-6 [10745645.001]
  • (PMID = 21333203.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3041046
  •  go-up   go-down


16. Locke JE, Barber LG: Comparative aspects and clinical outcomes of canine renal hemangiosarcoma. J Vet Intern Med; 2006 Jul-Aug;20(4):962-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative aspects and clinical outcomes of canine renal hemangiosarcoma.
  • BACKGROUND: Hemangiosarcoma (HSA) is a common solid tumor of the spleen, heart, and skin of dogs.
  • METHODS: Medical records from 1999 to 2004 were searched for dogs with histopathologically confirmed renal HSA, and data relevant to clinical signs, treatments, and outcomes were abstracted.
  • RESULTS: Clinical signs were nonspecific, and the median duration of clinical signs before diagnosis was 60 days.
  • One dog had pulmonary metastasis at diagnosis.
  • All dogs underwent nephrectomy, and 4/14 dogs also received adjunctive chemotherapy.
  • Median survival time of all dogs was 278 days (range 0-1,005 days), and dogs with hemoperitoneum had significantly shorter survival times than dogs without hemoperitoneum (62 days versus 286 days, P < .001).
  • CONCLUSIONS AND CLINICAL IMPORTANCE: These results indicate that hemoperitoneum and distant metastasis at diagnosis appear to occur less frequently in dogs with renal HSA compared with other visceral forms of HSA.
  • Furthermore, dogs with renal HSA have protracted disease progression, with improved 1-year survival rates and longer median survival time compared to dogs with splenic, cardiac, and retroperitoneal HSA.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955823.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Koutelidakis IM, Tsiaousis PZ, Papaziogas BT, Patsas AG, Atmatzidis SK, Atmatzidis KS: Spleen rupture due to primary angiosarcoma: a case report. J Gastrointest Cancer; 2007;38(2-4):74-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen rupture due to primary angiosarcoma: a case report.
  • A case of a 79-year-old female with rupture of the spleen due to primary angiosarcoma is presented.
  • Diagnosis was based on histology postoperatively.
  • Primary angiosarcoma of the spleen is a very rare and aggressive neoplasm with a high metastatic rate and almost uniformly fatal.
  • Due to small number of reported cases, there are no guidelines concerning adjuvant or palliative treatment or any beneficial protocols of chemotherapy or radiotherapy up to date.
  • [MeSH-major] Hemangiosarcoma / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology
  • [MeSH-minor] Aged. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Chirurg. 2004 Jan;75(1):70-4 [14740131.001]
  • [Cites] N Z Med J. 2004 Oct 08;117(1203):U1103 [15477927.001]
  • [Cites] Acta Biomed Ateneo Parmense. 2000;71(5):135-40 [11450114.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Radiology. 2005 Apr;235(1):106-15 [15749977.001]
  • [Cites] J Natl Med Assoc. 2000 Mar;92(3):143-6 [10745645.001]
  • [Cites] J Surg Oncol. 2005 Dec 15;92(4):312-6 [16299797.001]
  • [Cites] AJR Am J Roentgenol. 1982 May;138(5):965-6 [6979189.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Rev Med Interne. 2000 Sep;21(9):809-11 [11039181.001]
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):283-5 [10823452.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):951-9 [14674062.001]
  • [Cites] Ulus Travma Acil Cerrahi Derg. 2007 Oct;13(4):313-5 [17978914.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1054-6 [16048401.001]
  • (PMID = 19016352.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • Primary angiosarcomas of the spleen are rare and almost always fatal.
  • The mean age of patients at presentation is 59 years and the major clinical findings include abdominal pain, splenic rupture, and splenomegaly.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • The worst prognostic factor is splenic rupture with early metastasis.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


19. Vakkalanka B, Milhem M: Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. Clin Med Insights Oncol; 2010 Oct 12;4:107-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review.
  • INTRODUCTION: Splenic angiosarcoma is a rare tumor with only a few cases reported in the literature.
  • We report a case of a locally advanced angiosarcoma rendered operable by treatment with Paclitaxel monotherapy.
  • CASE PRESENTATION: A 69 year old female presented with a high grade splenic angiosarcoma, considered inoperable due to the extent of local spread.
  • CONCLUSION: Chemotherapy options for splenic angiosarcoma are not well studied.
  • Paclitaxel as monotherapy is a useful therapeutic option in down staging tumors, facilitating surgical resection and merits further study in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981134.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2956477
  • [Keywords] NOTNLM ; angiosarcoma / paclitaxel / sarcoma / spleen
  •  go-up   go-down


20. Hai SA, Genato R, Gressel I, Khan P: Primary splenic angiosarcoma: case report and literature review. J Natl Med Assoc; 2000 Mar;92(3):143-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic angiosarcoma: case report and literature review.
  • Angiosarcoma of the spleen is a rare neoplasm.
  • Generally, this cancer has a poor prognosis and prompt splenectomy offers the only cure, as the cancer is poorly responsive to adjuvant chemotherapy.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Acta Chir Scand. 1988 Jul-Aug;154(7-8):477-9 [3188797.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):229-42 [6285748.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):34-42 [2294841.001]
  • [Cites] Gastrointest Radiol. 1990 Winter;15(1):43-6 [2298353.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Br J Surg. 1952 Jul;40(159):68-70 [14944798.001]
  • [Cites] South Med J. 1995 Aug;88(8):873-5 [7631220.001]
  • [Cites] Acta Radiol. 1994 Sep;35(5):455-8 [8086253.001]
  • (PMID = 10745645.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2640552
  •  go-up   go-down


21. Spugnini EP, Esposito V, Groeger AM, Cassandro R, Onori N, Chirianni A, Baldi A: Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. In Vivo; 2006 Jan-Feb;20(1):125-7
Hazardous Substances Data Bank. INDINAVIR SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma.
  • HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles.
  • A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm.
  • [MeSH-major] Dog Diseases / drug therapy. HIV Protease Inhibitors / therapeutic use. Hemangiosarcoma / drug therapy. Indinavir / therapeutic use. Splenic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433040.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HIV Protease Inhibitors; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 5W6YA9PKKH / Indinavir
  •  go-up   go-down


22. Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med; 2000 May-Jun;14(3):271-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ifosfamide for treatment of various canine neoplasms.
  • Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma.
  • Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days.
  • No dog developed clinical or microscopic evidence of hemorrhagic cystitis.
  • Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830540.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Song SY, Ko YH, Ahn G: Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol; 2005 Jul;13(3):299-303
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association.
  • We present an unusual association of mediastinal germ cell tumor containing seminoma and angiosarcoma components and splenic histiocytic sarcoma.
  • Histopathologically, an anterior mediastinal mass contained typical seminoma, immature teratoma, embryonal carcinoma, angiosarcoma, yolk sac tumor, and polyembryoma.
  • An abdominal ultrasonogram revealed a huge splenomegaly with multiple ill-defined low echogenic nodules, 1 month after the second cycle of chemotherapy.
  • [MeSH-major] Hemangiosarcoma / pathology. Histiocytic Sarcoma / pathology. Mediastinal Neoplasms / pathology. Seminoma / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasms, Multiple Primary. Splenomegaly. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086090.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


24. Di Matteo FM, De Stefano M, Vanni B, Palermo S, Biancafarina A, Giusti D, Savino G, Di Marco C, Casalvieri L, De Antoni E: [Retroperitoneal giant mixed sarcoma. Case report]. G Chir; 2008 May;29(5):238-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT scan showed a solid abdominal expansive mass, with compression and displacement of the left lobe of the liver, spleen, stomach, pancreas, and left kidney.
  • Histology showed a mixed liposarcoma and angiosarcoma with high grade of malignancy and positivity for vimentin, factor VIII, CD34, CD31 and negativity for S-100, CD68, AMS, AML.
  • The prognosis of these tumours is closely related to local recurrence, histological type, size and radical surgery.
  • Radiation therapy and chemotherapy do not seem to have a strong influence on the prognosis.
  • An aggressive surgical approach is the first choice for the treatment of such tumors.
  • [MeSH-major] Hemangiosarcoma / surgery. Liposarcoma / surgery. Neoplasms, Multiple Primary / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507961.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement